Catch up with this week’s top pharma news! A Convergence Science Centre is launched to accelerate cancer treatments, Switzerland and Lichtenstein’s Director for International Trade says the UK offers unique opportunities for export and investment, and Pfizer confirms its generics merger with Mylan.
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Head of Business Development, Ryan Wooller, at firstname.lastname@example.org, or get in touch on 07748 464 079.
On the hunt for a new role, or just curious?
Visit our candidate page, submit your CV to email@example.com, or give our offices a ring!
Pfizer and Mylan have announced an all-stock deal that would combine their off-patent medicines businesses, confirming speculation that emerged over the weekend.
A no-deal departure from the EU, resulting in tariffs and customs checks, would be a serious problem for many manufacturers, who rely on frictionless trade to source components and export goods.
Scientists are re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles – without the need for invasive surgery.
Director DIT for Switzerland and Liechtenstein, Noel McEvoy, argues in the Swiss Export Journal that the UK offers unique opportunities for export and investment for Swiss businesses.
Cancer Research UK has announced that incidences of melanoma have increased by 45% since 2004.
While you’re here…
…and are interested in our content, why not sign up to our newsletter?
It'sjust below here.